Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-101 for prevention of respiratory and COVID-19 infections in cancer patients
NCT04442048Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2020
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IMM-101 in coronavirus disease 2019 (COVID-19), respiratory tract infection (RTI), sponsored by Canadian Cancer Trials Group. Started Oct 2020; status: completed.
02
Drugs
IMM-101
03
Conditions
coronavirus disease 2019 (COVID-19)respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT04442048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442048.